View ValuationBINEX 향후 성장Future 기준 점검 0/6BINEX의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장20.6%매출 성장률13.7%향후 자기자본이익률6.01%애널리스트 커버리지Low마지막 업데이트01 Apr 2026최근 향후 성장 업데이트Price Target Changed • Oct 01Price target decreased by 7.9% to ₩24,500Down from ₩26,600, the current price target is provided by 1 analyst. New target price is 53% above last closing price of ₩16,010. Stock is down 33% over the past year. The company posted a net loss per share of ₩1,126 last year.Price Target Changed • Apr 03Price target decreased by 15% to ₩27,750Down from ₩32,500, the current price target is an average from 2 analysts. New target price is 95% above last closing price of ₩14,200. Stock is up 4.6% over the past year. The company posted a net loss per share of ₩1,126 last year.모든 업데이트 보기Recent updates공시 • Mar 06BINEX Co., Ltd., Annual General Meeting, Mar 23, 2026BINEX Co., Ltd., Annual General Meeting, Mar 23, 2026, at 09:30 Tokyo Standard Time. Location: auditorium, 368-3, dadae-ro, saha-gu, busan South Korea공시 • Oct 28BINEX Co., Ltd. announced that it expects to receive KRW 15.548248544 billion in fundingBINEX Co., Ltd. announced a private placement of LIFE Offering of KRW 15,548,248,544 by issuance of Unregistered No Interest No Guarantee Private Exchangeable Bonds on October 28, 2025. The bonds are 100% convertible into Common Shares of the company at a conversion value of KRW 18,587 to issue 836,512 Common Shares of the company. The exchange billing period starts from December 06, 2025 through October 06, 2030. The transaction includes participation from investor Samsung Securities Co., Ltd.Price Target Changed • Oct 01Price target decreased by 7.9% to ₩24,500Down from ₩26,600, the current price target is provided by 1 analyst. New target price is 53% above last closing price of ₩16,010. Stock is down 33% over the past year. The company posted a net loss per share of ₩1,126 last year.분석 기사 • Aug 20BINEX Co., Ltd.'s (KOSDAQ:053030) Price In Tune With RevenuesKOSDAQ:A053030 1 Year Share Price vs Fair Value Explore BINEX's Fair Values from the Community and select yours When...분석 기사 • May 15Would BINEX (KOSDAQ:053030) Be Better Off With Less Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Price Target Changed • Apr 03Price target decreased by 15% to ₩27,750Down from ₩32,500, the current price target is an average from 2 analysts. New target price is 95% above last closing price of ₩14,200. Stock is up 4.6% over the past year. The company posted a net loss per share of ₩1,126 last year.New Risk • Mar 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).Reported Earnings • Mar 20Full year 2024 earnings released: ₩1,126 loss per share (vs ₩151 profit in FY 2023)Full year 2024 results: ₩1,126 loss per share (down from ₩151 profit in FY 2023). Revenue: ₩130.1b (down 16% from FY 2023). Net loss: ₩35.1b (down ₩39.7b from profit in FY 2023). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.공시 • Mar 06BINEX Co., Ltd., Annual General Meeting, Mar 24, 2025BINEX Co., Ltd., Annual General Meeting, Mar 24, 2025, at 09:30 Tokyo Standard Time. Location: auditorium, 368-3, dadae-ro, saha-gu, busan South Korea분석 기사 • Mar 05What You Can Learn From BINEX Co., Ltd.'s (KOSDAQ:053030) P/S After Its 25% Share Price CrashBINEX Co., Ltd. ( KOSDAQ:053030 ) shares have had a horrible month, losing 25% after a relatively good period...분석 기사 • Feb 13Here's Why BINEX (KOSDAQ:053030) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Jan 08Revenues Tell The Story For BINEX Co., Ltd. (KOSDAQ:053030) As Its Stock Soars 35%BINEX Co., Ltd. ( KOSDAQ:053030 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...분석 기사 • Nov 18BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price PlummetBINEX Co., Ltd. ( KOSDAQ:053030 ) shareholders that were waiting for something to happen have been dealt a blow with a...New Risk • Nov 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding).분석 기사 • Oct 23Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Sep 01Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%BINEX Co., Ltd. ( KOSDAQ:053030 ) shares have continued their recent momentum with a 25% gain in the last month alone...분석 기사 • Jul 01Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%BINEX Co., Ltd. ( KOSDAQ:053030 ) shareholders would be excited to see that the share price has had a great month...New Risk • May 21New major risk - Revenue and earnings growthEarnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 10% per year over the past 5 years.분석 기사 • Apr 17BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some RiskBINEX Co., Ltd. ( KOSDAQ:053030 ) shares have retraced a considerable 30% in the last month, reversing a fair amount of...분석 기사 • Mar 22We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish EarningsDespite BINEX Co., Ltd.'s ( KOSDAQ:053030 ) recent earnings report having lackluster headline numbers, the market...Reported Earnings • Mar 20Full year 2023 earnings released: EPS: ₩151 (vs ₩402 in FY 2022)Full year 2023 results: EPS: ₩151 (down from ₩402 in FY 2022). Revenue: ₩154.8b (down 1.2% from FY 2022). Net income: ₩4.67b (down 63% from FY 2022). Profit margin: 3.0% (down from 7.9% in FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 5% per year.분석 기사 • Feb 26BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch UpThe BINEX Co., Ltd. ( KOSDAQ:053030 ) share price has done very well over the last month, posting an excellent gain of...Reported Earnings • May 15First quarter 2023 earnings released: EPS: ₩228 (vs ₩61.00 in 1Q 2022)First quarter 2023 results: EPS: ₩228 (up from ₩61.00 in 1Q 2022). Revenue: ₩48.2b (up 37% from 1Q 2022). Net income: ₩7.06b (up 275% from 1Q 2022). Profit margin: 15% (up from 5.3% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩10,770, the stock trades at a trailing P/E ratio of 26.8x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 13% over the past three years.Buying Opportunity • Mar 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩11,598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 22% in 2 years. Earnings is forecast to grow by 70% in the next 2 years.Buying Opportunity • Nov 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be ₩13,967, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 22% in 2 years. Earnings is forecast to grow by 69% in the next 2 years.Reported Earnings • Nov 20Third quarter 2022 earnings released: EPS: ₩170 (vs ₩159 in 3Q 2021)Third quarter 2022 results: EPS: ₩170 (up from ₩159 in 3Q 2021). Revenue: ₩39.5b (up 18% from 3Q 2021). Net income: ₩5.24b (up 5.9% from 3Q 2021). Profit margin: 13% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 14% per year.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩14,950, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 59% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Buying Opportunity • Mar 18Now 22% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩19,921, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% per annum over the last 3 years. The company has become profitable over the last 3 years.Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩14,200, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩14,300, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 28% over the past three years.분석 기사 • Mar 18Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩206 (vs ₩273 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩133.0b (up 6.2% from FY 2019). Net income: ₩6.41b (down 25% from FY 2019). Profit margin: 4.8% (down from 6.8% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment deteriorated over the past weekAfter last week's 49% share price decline to ₩14,500, the stock is trading at a trailing P/E ratio of 32.4x, down from the previous P/E ratio of 63.4x. This compares to an average P/E of 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 28%.Is New 90 Day High Low • Mar 10New 90-day low: ₩16,250The company is down 45% from its price of ₩29,400 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 23% over the same period.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩26,650, the stock is trading at a trailing P/E ratio of 59.5x, down from the previous P/E ratio of 73.7x. This compares to an average P/E of 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 148%.Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩32,900, the stock is trading at a trailing P/E ratio of 73.4x, up from the previous P/E ratio of 61.4x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 199%.Is New 90 Day High Low • Feb 10New 90-day high: ₩32,900The company is up 18% from its price of ₩27,950 on 12 November 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.분석 기사 • Jan 28If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain TodayWhen you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...분석 기사 • Dec 24Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?BINEX (KOSDAQ:053030) has had a rough month with its share price down 15%. However, stock prices are usually driven by...Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 15% share price decline to ₩23,400, the stock is trading at a trailing P/E ratio of 63.7x, down from the previous P/E ratio of 75x. This compares to an average P/E of 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 163%.공시 • Oct 07BINEX Co., Ltd. announced that it has received KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.On October 6, 2020, BINEX Co., Ltd. (KOSDAQ:A053030) closed the transaction.공시 • Sep 29BINEX Co., Ltd. announced that it expects to receive KRW 12 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.BINEX Co., Ltd. (KOSDAQ:A053030) announced private placement of series 6 non-guaranteed private equity exchange bonds for gross proceeds of KRW 12,000,000,000 on September 28, 2020. The transaction will include participation from new investors Kiwoom Securities Co., Ltd. (KOSE:A039490) for KRW 2,000,000,000, Kiwoom Private Equity Aju First New Technology Business Investment Association, a fund co-managed by Kiwoom Private Equity, Inc. and existing investor Aju IB Investment Co., Ltd. (KOSDAQ:A027360) for KRW 10,000,000,000. The bonds will be issued at par and does not bears any interest. The bonds will mature on October 6, 2025 and is redeemable at par on certain dates. The bonds are convertible into 387,722 shares representing 1.21% stake in the company, at a fixed conversion price of KRW 30,950 per share starting from April 6, 2021 and ending on September 6, 2025. The expected payment date is October 6, 2020. The transaction has been approved by the board of directors of the company.이익 및 매출 성장 예측KOSDAQ:A053030 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028255,813N/AN/AN/A112/31/2027227,507N/AN/AN/A112/31/2026199,079N/AN/AN/A112/31/2025168,475-3,226-46,533-23,268N/A9/30/2025165,636-7,702-29,198-7,847N/A6/30/2025153,184-18,548-33,405-17,966N/A3/31/2025140,128-25,287-33,275-19,475N/A12/31/2024130,051-35,071-20,778-9,426N/A9/30/2024129,614-25,173-34,236-23,083N/A6/30/2024128,302-18,860-36,795-23,114N/A3/31/2024136,335-12,165-17,840-4,322N/A12/31/2023154,8254,671-12,3773,778N/A9/30/2023160,7852,845-8,64711,421N/A6/30/2023168,71513,451-29022,993N/A3/31/2023169,56617,625-17,56113,061N/A12/31/2022156,67712,445-19,39117,062N/A9/30/2022154,96916,511-7,05628,985N/A6/30/2022148,84716,354-9,89321,913N/A3/31/2022137,08112,565-3,39823,448N/A12/31/2021134,39919,0948,85028,630N/A9/30/2021129,47410,144-9,3569,669N/A6/30/2021129,0319,39049316,968N/A3/31/2021134,42413,27813,88425,530N/A12/31/2020132,9766,41210,37219,918N/A9/30/2020131,55013,97015,45318,834N/A6/30/2020129,09711,4639,84217,084N/A3/31/2020127,0648,7351,17710,174N/A12/31/2019125,2598,5041,76010,785N/A9/30/2019122,94213,092N/A19,557N/A6/30/2019119,09913,565N/A16,314N/A3/31/2019111,2038,878N/A17,211N/A12/31/2018104,0436,337N/A13,561N/A9/30/201891,167-4,232N/A5,127N/A6/30/201884,136-9,325N/A7,163N/A3/31/201879,031-12,419N/A3,341N/A12/31/201778,026-10,797N/A8,136N/A6/30/201780,782-7,528N/A13,053N/A3/31/201781,500-3,065N/A10,766N/A12/31/201680,924-3,144N/A3,799N/A9/30/201677,576-12,169N/A6,256N/A6/30/201674,890-10,196N/A-4,899N/A3/31/201671,804-9,553N/A-5,623N/A12/31/201566,539-9,289N/A-4,497N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A053030 의 예상 수익 증가율이 절약률(3.1%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: A053030 의 수익이 KR 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: A053030 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: A053030 의 수익(연간 13.7%)이 KR 시장(연간 15.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: A053030 의 수익(연간 13.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A053030의 자본 수익률은 3년 후 6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 02:29종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BINEX Co., Ltd.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Heeyoung LeeDaishin Securities Co. Ltd.Sung Hwan ChoiKyobo Securities Co., LtdMi Hyun KimMorgan Stanley
Price Target Changed • Oct 01Price target decreased by 7.9% to ₩24,500Down from ₩26,600, the current price target is provided by 1 analyst. New target price is 53% above last closing price of ₩16,010. Stock is down 33% over the past year. The company posted a net loss per share of ₩1,126 last year.
Price Target Changed • Apr 03Price target decreased by 15% to ₩27,750Down from ₩32,500, the current price target is an average from 2 analysts. New target price is 95% above last closing price of ₩14,200. Stock is up 4.6% over the past year. The company posted a net loss per share of ₩1,126 last year.
공시 • Mar 06BINEX Co., Ltd., Annual General Meeting, Mar 23, 2026BINEX Co., Ltd., Annual General Meeting, Mar 23, 2026, at 09:30 Tokyo Standard Time. Location: auditorium, 368-3, dadae-ro, saha-gu, busan South Korea
공시 • Oct 28BINEX Co., Ltd. announced that it expects to receive KRW 15.548248544 billion in fundingBINEX Co., Ltd. announced a private placement of LIFE Offering of KRW 15,548,248,544 by issuance of Unregistered No Interest No Guarantee Private Exchangeable Bonds on October 28, 2025. The bonds are 100% convertible into Common Shares of the company at a conversion value of KRW 18,587 to issue 836,512 Common Shares of the company. The exchange billing period starts from December 06, 2025 through October 06, 2030. The transaction includes participation from investor Samsung Securities Co., Ltd.
Price Target Changed • Oct 01Price target decreased by 7.9% to ₩24,500Down from ₩26,600, the current price target is provided by 1 analyst. New target price is 53% above last closing price of ₩16,010. Stock is down 33% over the past year. The company posted a net loss per share of ₩1,126 last year.
분석 기사 • Aug 20BINEX Co., Ltd.'s (KOSDAQ:053030) Price In Tune With RevenuesKOSDAQ:A053030 1 Year Share Price vs Fair Value Explore BINEX's Fair Values from the Community and select yours When...
분석 기사 • May 15Would BINEX (KOSDAQ:053030) Be Better Off With Less Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Price Target Changed • Apr 03Price target decreased by 15% to ₩27,750Down from ₩32,500, the current price target is an average from 2 analysts. New target price is 95% above last closing price of ₩14,200. Stock is up 4.6% over the past year. The company posted a net loss per share of ₩1,126 last year.
New Risk • Mar 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
Reported Earnings • Mar 20Full year 2024 earnings released: ₩1,126 loss per share (vs ₩151 profit in FY 2023)Full year 2024 results: ₩1,126 loss per share (down from ₩151 profit in FY 2023). Revenue: ₩130.1b (down 16% from FY 2023). Net loss: ₩35.1b (down ₩39.7b from profit in FY 2023). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
공시 • Mar 06BINEX Co., Ltd., Annual General Meeting, Mar 24, 2025BINEX Co., Ltd., Annual General Meeting, Mar 24, 2025, at 09:30 Tokyo Standard Time. Location: auditorium, 368-3, dadae-ro, saha-gu, busan South Korea
분석 기사 • Mar 05What You Can Learn From BINEX Co., Ltd.'s (KOSDAQ:053030) P/S After Its 25% Share Price CrashBINEX Co., Ltd. ( KOSDAQ:053030 ) shares have had a horrible month, losing 25% after a relatively good period...
분석 기사 • Feb 13Here's Why BINEX (KOSDAQ:053030) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
분석 기사 • Jan 08Revenues Tell The Story For BINEX Co., Ltd. (KOSDAQ:053030) As Its Stock Soars 35%BINEX Co., Ltd. ( KOSDAQ:053030 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...
분석 기사 • Nov 18BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price PlummetBINEX Co., Ltd. ( KOSDAQ:053030 ) shareholders that were waiting for something to happen have been dealt a blow with a...
New Risk • Nov 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding).
분석 기사 • Oct 23Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Sep 01Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%BINEX Co., Ltd. ( KOSDAQ:053030 ) shares have continued their recent momentum with a 25% gain in the last month alone...
분석 기사 • Jul 01Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%BINEX Co., Ltd. ( KOSDAQ:053030 ) shareholders would be excited to see that the share price has had a great month...
New Risk • May 21New major risk - Revenue and earnings growthEarnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 10% per year over the past 5 years.
분석 기사 • Apr 17BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some RiskBINEX Co., Ltd. ( KOSDAQ:053030 ) shares have retraced a considerable 30% in the last month, reversing a fair amount of...
분석 기사 • Mar 22We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish EarningsDespite BINEX Co., Ltd.'s ( KOSDAQ:053030 ) recent earnings report having lackluster headline numbers, the market...
Reported Earnings • Mar 20Full year 2023 earnings released: EPS: ₩151 (vs ₩402 in FY 2022)Full year 2023 results: EPS: ₩151 (down from ₩402 in FY 2022). Revenue: ₩154.8b (down 1.2% from FY 2022). Net income: ₩4.67b (down 63% from FY 2022). Profit margin: 3.0% (down from 7.9% in FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 5% per year.
분석 기사 • Feb 26BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch UpThe BINEX Co., Ltd. ( KOSDAQ:053030 ) share price has done very well over the last month, posting an excellent gain of...
Reported Earnings • May 15First quarter 2023 earnings released: EPS: ₩228 (vs ₩61.00 in 1Q 2022)First quarter 2023 results: EPS: ₩228 (up from ₩61.00 in 1Q 2022). Revenue: ₩48.2b (up 37% from 1Q 2022). Net income: ₩7.06b (up 275% from 1Q 2022). Profit margin: 15% (up from 5.3% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩10,770, the stock trades at a trailing P/E ratio of 26.8x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 13% over the past three years.
Buying Opportunity • Mar 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩11,598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 22% in 2 years. Earnings is forecast to grow by 70% in the next 2 years.
Buying Opportunity • Nov 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be ₩13,967, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 22% in 2 years. Earnings is forecast to grow by 69% in the next 2 years.
Reported Earnings • Nov 20Third quarter 2022 earnings released: EPS: ₩170 (vs ₩159 in 3Q 2021)Third quarter 2022 results: EPS: ₩170 (up from ₩159 in 3Q 2021). Revenue: ₩39.5b (up 18% from 3Q 2021). Net income: ₩5.24b (up 5.9% from 3Q 2021). Profit margin: 13% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 14% per year.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩14,950, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 59% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Buying Opportunity • Mar 18Now 22% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩19,921, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% per annum over the last 3 years. The company has become profitable over the last 3 years.
Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩14,200, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩14,300, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 28% over the past three years.
분석 기사 • Mar 18Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩206 (vs ₩273 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩133.0b (up 6.2% from FY 2019). Net income: ₩6.41b (down 25% from FY 2019). Profit margin: 4.8% (down from 6.8% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment deteriorated over the past weekAfter last week's 49% share price decline to ₩14,500, the stock is trading at a trailing P/E ratio of 32.4x, down from the previous P/E ratio of 63.4x. This compares to an average P/E of 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 28%.
Is New 90 Day High Low • Mar 10New 90-day low: ₩16,250The company is down 45% from its price of ₩29,400 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 23% over the same period.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩26,650, the stock is trading at a trailing P/E ratio of 59.5x, down from the previous P/E ratio of 73.7x. This compares to an average P/E of 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 148%.
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩32,900, the stock is trading at a trailing P/E ratio of 73.4x, up from the previous P/E ratio of 61.4x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 199%.
Is New 90 Day High Low • Feb 10New 90-day high: ₩32,900The company is up 18% from its price of ₩27,950 on 12 November 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
분석 기사 • Jan 28If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain TodayWhen you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
분석 기사 • Dec 24Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?BINEX (KOSDAQ:053030) has had a rough month with its share price down 15%. However, stock prices are usually driven by...
Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 15% share price decline to ₩23,400, the stock is trading at a trailing P/E ratio of 63.7x, down from the previous P/E ratio of 75x. This compares to an average P/E of 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 163%.
공시 • Oct 07BINEX Co., Ltd. announced that it has received KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.On October 6, 2020, BINEX Co., Ltd. (KOSDAQ:A053030) closed the transaction.
공시 • Sep 29BINEX Co., Ltd. announced that it expects to receive KRW 12 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.BINEX Co., Ltd. (KOSDAQ:A053030) announced private placement of series 6 non-guaranteed private equity exchange bonds for gross proceeds of KRW 12,000,000,000 on September 28, 2020. The transaction will include participation from new investors Kiwoom Securities Co., Ltd. (KOSE:A039490) for KRW 2,000,000,000, Kiwoom Private Equity Aju First New Technology Business Investment Association, a fund co-managed by Kiwoom Private Equity, Inc. and existing investor Aju IB Investment Co., Ltd. (KOSDAQ:A027360) for KRW 10,000,000,000. The bonds will be issued at par and does not bears any interest. The bonds will mature on October 6, 2025 and is redeemable at par on certain dates. The bonds are convertible into 387,722 shares representing 1.21% stake in the company, at a fixed conversion price of KRW 30,950 per share starting from April 6, 2021 and ending on September 6, 2025. The expected payment date is October 6, 2020. The transaction has been approved by the board of directors of the company.